397 related articles for article (PubMed ID: 33198444)
1. Hepatitis C virus-related cryoglobulinemic vasculitis.
Mazzaro C; Mauro E; Ermacora A; Doretto P; Fumagalli S; Tonizzo M; Toffolutti F; Gattei V
Minerva Med; 2021 Apr; 112(2):175-187. PubMed ID: 33198444
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy.
Mazzaro C; Dal Maso L; Mauro E; Visentini M; Tonizzo M; Gattei V; Andreone P; Pozzato G
Autoimmun Rev; 2020 Aug; 19(8):102589. PubMed ID: 32540448
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Delluc A; Piette JC; Cacoub P
Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
[TBL] [Abstract][Full Text] [Related]
4. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
Benstead TJ; Chalk CH; Parks NE
Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
[TBL] [Abstract][Full Text] [Related]
5. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P
J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523
[TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment].
Gordovskaia NB; Kozlovskaia LV; Milovanova SIu; Ignatova TM; Korotchaeva IuV
Ter Arkh; 2013; 85(6):78-84. PubMed ID: 23866603
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ
Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241
[TBL] [Abstract][Full Text] [Related]
8. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.
Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P
J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864
[TBL] [Abstract][Full Text] [Related]
9. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.
Levine JW; Gota C; Fessler BJ; Calabrese LH; Cooper SM
J Rheumatol; 2005 Jun; 32(6):1164-7. PubMed ID: 15940780
[TBL] [Abstract][Full Text] [Related]
10. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements.
Dammacco F; Lauletta G; Vacca A
Clin Exp Med; 2023 Jun; 23(2):255-272. PubMed ID: 35348938
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F
Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of different antiviral treatment protocols in HCV related cryoglobulinemic vasculitis.
Allam WR; Hegazy MT; Hussein MA; Zoheir N; Quartuccio L; El-Khamisy SF; Ragab G
Sci Rep; 2024 May; 14(1):11840. PubMed ID: 38782988
[TBL] [Abstract][Full Text] [Related]
13. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
[TBL] [Abstract][Full Text] [Related]
14. The dilemma of treating hepatitis C virus-associated cryoglobulinemia.
Roccatello D; Fenoglio R; Sciascia S
Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590
[TBL] [Abstract][Full Text] [Related]
15. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.
Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S
Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112
[TBL] [Abstract][Full Text] [Related]
16. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient.
Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M
J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223
[TBL] [Abstract][Full Text] [Related]
17. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies.
Fabrizi F; Dixit V; Messa P
J Med Virol; 2013 Jun; 85(6):1019-27. PubMed ID: 23588727
[TBL] [Abstract][Full Text] [Related]
18. Recent news in the treatment of hepatitis B virus-related cryogobulinemic vasculitis.
Mazzaro C; Dal Maso L; Visentini M; Ermacora A; Tonizzo M; Gattei V; Andreone P
Minerva Med; 2020 Dec; 111(6):566-572. PubMed ID: 32573522
[TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.
Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P
Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study.
Mazzaro C; Dal Maso L; Quartuccio L; Ghersetti M; Lenzi M; Mauro E; Bond M; Casarin P; Gattei V; Crosato IM; De Vita S; Pozzato G
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):107-114. PubMed ID: 29465371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
